ABSTRACT Diazoxide was injected into the pulmonary artery in nine patients with primary pulmonary hypertension. There was no significant change in pulmonary artery pressure, which fell by more than 10 mmHg in only two patients. The explained pulmonary hypertension. All nine patients had a diagnostic cardiac catheterisation, and pulmonary arteriograms were obtained in seven of these. In none was there any evidence of an underlying congenital cardiac lesion, pulmonary thromboem1bolism, or pulmonary veno-occlusive disease. One patient (case 6) had chronic partially reversible airways obstruction, but the disturbance of lung function was insufficient to account for severe pulmonary vascular disease. Three patients (cases 2, 3, and 5) have died and two were examined postmortem. In one of these (case 5) pulmonary function studies during life suggested that vascular obstruction was at capillary level, and necropsy examination did not show the plexogenic pulmonary arteriopathy characteristic of "classical primary pulmonary hypertension." In the other (case 2), the necropsy appearances were typical of primary pulmonary hypertension with plexiform and dilatation lesions but without necrotising arteritis.
Diazoxide is a benzothiadiazine derivative related to the thiazide diuretics but without diuretic activity.' It is a potent dilator of resistance vessels and has been widely used intravenously in the treatment of acute hypersensitive emergencies. 2 Though it has been shown to be effective orally in the treatment of systemic hypertension,3 4 it was found to cause diabetes and for this reason never came into general use. There is no consistently effective treatment for primary pulmonary hypertension, but recently Wang et al5 have reported a reduction in pulmonary vascular resistance after injection of diazoxide, and clinical improvement in two out of three patients. After these observations, we have administered diazoxide to nine patients with primary pulmonary hypertension.
Patients and methods
Nine patients gave informed consent to taking part in the investigation. All were women, aged from 25 to 62 years. Seven were European (five British or Irish, one Icelandic); one was from Sri Lanka and one an Indian from East Africa, but in neither was there any evidence of filariasis. All had the clinical features of primary or un-explained pulmonary hypertension. All nine patients had a diagnostic cardiac catheterisation, and pulmonary arteriograms were obtained in seven of these. In none was there any evidence of an underlying congenital cardiac lesion, pulmonary thromboem1bolism, or pulmonary veno-occlusive disease. One patient (case 6) had chronic partially reversible airways obstruction, but the disturbance of lung function was insufficient to account for severe pulmonary vascular disease. Three patients (cases 2, 3, and 5) have died and two were examined postmortem. In one of these (case 5) pulmonary function studies during life suggested that vascular obstruction was at capillary level, and necropsy examination did not show the plexogenic pulmonary arteriopathy characteristic of "classical primary pulmonary hypertension." In the other (case 2), the necropsy appearances were typical of primary pulmonary hypertension with plexiform and dilatation lesions but without necrotising arteritis. (TABLE 2) In five patients, symptoms (exertional breathlessness, syncope or near-syncope, and chest pain) were unimproved by diazoxide in the maximum tolerated dose. Further increase in dose was prohibited by serious side effects in all these cases. Nausea and sickness was severe in two and postural hypotension was severe in case 7, who had shown the greatest fall in systemic blood pressure during the initial study. Three patients became diabetic; two in whom treat- 
Diazoxide in primary pulmonary hypertension ment was continued required insulin and glibenclamide for control of hyperglycaemia. Four patients developed signs of fluid retention; three required large doses of potent diuretics for control of oedema, and the other deteriorated progressively with signs of increasing heart failure. Diazoxide was eventually discontinued in all, and three of these four patients subsequently died, one (case 5) within three weeks of stopping treatment and the others (cases 2 and 3) 10 and 12 months later.
Two patients have improved, one dramatically.
This young woman (case 4) from Sri Lanka was so severely disabled by breathlessness, chest pain, and syncope on the slightest exertion that lung transplantation was seriously considered. On treatment, there was a striking improvement in exercise tolerance: she was less breathless and no longer had syncope or chest pain on effort. She could walk one mile on the level and climb stairs, and married. At first, she attributed headache to the treatment, but the only definite side effect was a profuse growth of hair on the face and limbs, because of which she was unwilling to increase the dose above 300 mg bd. The other patient (case 6) who improved was also treated with salbutamol, sodium cromoglycate, and beclomethasone inhalations, with some symptomatic and objective improvement in airways obstruction, before starting diazoxide treatment. Symptomatic improvement continued when diazoxide was started, but she has needed regular diuretic therapy to control fluid retention, particularly during exacerbations of bronchitis. She has also noticed increased growth of hair on the face and arms. REINVESTIGATION [4] [5] [6] Pulmonary artery pressure before administration of parenteral diazoxide was unchanged from (or slightly higher than) control pulmonary artery pressure in the pretreatment stud-y in four of the five patients. In three of these four patients, pulmonary artery pressure on oral diazoxide was higher than after parenteral diazoxide in the pretreatment study. In all these three, there was a conspicuous fall in pulmonary artery pressure with parenteral diazoxide (20 to 28 mmHg), greater in each case than the fall in pulmonary artery pressure with parenteral diazoxide before starting oral treatment. In one patient (case 2) pulmonary artery pressure was lower on oral diazoxide than in the pretreatment study, either before or after parenteral diazoxide. to 2 1 1/min), the average value rising from 3-2 to 4-5 1/min. There was, however, a further increase in pulmonary blood flow (04 to 3d1 1/min) after parenteral diazoxide, the average value rising to 6-3 1/min.
Likewise, pulmonary vascular resistance was lower than before treatment in four of the five patients, the fall ranging from 3-9 to 12-9 units. In the other patient, who could tolerate only a small dose (50 mg bd), there was no change. In all five cases, there was a further fall in pulmonary vascular resistance with parenteral diazoxide.
One patient (case 4) had a second re-study while continuing oral diazoxide treatment. On this occasion, the fall in pulmonary vascular resistance was less than at the first re-study; it is perhaps relevant that on this occasion the dose of oral diazoxide was omitted on the morning of investigation.
Discussion
Though acetylcholine injected directly into the pulmonary artery in patients with mitral stenosis or primary pulmonary hypertension causes a fall in pulmonary artery pressure and vascular resistance,9 this drug is ineffective when given orally. Intravenous isoprenaline causes active pulmonary vasodilation'0 and lowers pulmonary vascular resistance in mitral valve disease and in primary pulmonary hypertension; Shettigar et all" found that sublingual isoprenaline given every two hours caused a sustained reduction in pulmonary artery pressure and pulmonary vascular resistance, and symptomatic improvement, in a patient with primary pulmonary hypertension. Tolazoline, an alpha-adrenergic antagonist, has been reported to reduce pulmonary artery pressure and vascular resistance in primary pulmonary hypertension11 12 and in other forms of pulmonary hypertension, but there have been no reports of successful long-term treatment with oral tolazoline. There is thus still a need for a potent pulmonary vasodilator which is effective when given orally as well as parenterally and can be given in adequate doses over a long period without side effects. Wang et a15 administered diazoxide parenterally and orally to three patients with primary pulmonary hypertension; all three responded in the acute experiment, one improved temporarily on oral treatment, and one obtained symptomatic benefit lasting over a period of nearly three years.
Our experience confirms that of Wang et al.5 There was no significant fall in pulmonary artery pressure after injection of diazoxide, though in two of the nine patients falls of 13 and 17 mmHg were recorded. However, there was a significant increase in pulmonary blood flow and a significant fall in pulmonary vascular resistance in the group as a whole, though the magnitude of the change varied widely in the individual patients. Though we did not measure pulmonary blood volume, we believe that the pulmonary vasodilatation resulting from diazoxide administration is an active process and not the passive consequence of an increase in pulmonary blood volume.'3 In all our patients there was, as expected, a concurrent fall in systemic arterial pressure, and the calculated fall in systemic resistance was greater than the fall in pulmonary resistance: this would be expected to lead to a shift in blood from pulmonary to systemic vascular bed.
Despite these encouraging results, only one patient (case 4) showed impressive clinical benefit on oral treatment with diazoxide. One other patient (case 6) improved, but was also having treatment for chronic asthma. These two patients both showed substantial falls in pulmonary vascular resistance not only with parenteral diazoxide, but also on oral treatment. Other patients did not respond clinically, despite comparable falls in pulmonary vascular resistance or-pulmonary artery pressure.
Failure of the other patients to respond may have resulted from their inability to take an adequate dose of the drug. This suggestion Diazoxide in primary pulmonary hypertension received support from the observation that at the time of the haemodynamic study during continued oral treatment, parenteral diazoxide resulted in further increase in pulmonary blood flow and fall in pulmonary vascular resistance. Wang et al5 found that a dose of 600 mg daily appeared to be necessary to maintain improvement and correlated this with blood levels exceeding 75 Ag/ml. We did not measure blood levels but found that only one of our patients was able to tolerate 600 mg daily and most had serious side effects at doses of 150 to 400 mg daily.
The relief of exertional syncope can readily be accounted for by the observed increase in cardiac output, resulting from a fall in pulmonary vascular resistance. It is less easy to explain the striking improvement in breathlessness observed by our most successful patient. The combined effect of a slight fall in pulmonary artery pressure and a large increase in pulmonary blood flow is a further increase in right ventricular work. For this reason, and because of the sodium and water retention diazoxide induces, it would not be unexpected if diazoxide therapy precipitated right heart failure in patients with primary pulmonary hypertension. In four of our patients, peripheral oedema appeared during treatment and required large doses of diuretics for its control.
In a disease with such a gloomy prognosis, it is a minor triumph if a new form of treatment can produce worthwhile and sustained improvement in even a small proportion of patients. In the combined experience of Wang et a15 and ourselves, two or three out of 12 patients had such a result, though even they still have severe pulmonary arterial hypertension. Our experience suggests that the search for a more effective and less toxic pulmonary vasodilator should be rewarding. Other vasodilators highly effective in the treatment of systemic hypertension appear worthy of study and in particular minoxidil has been shown to reduce pulmonary vascular resistance in the experimental animal.14 Little is known of the pathogenesis of primary pulmonary hypertension, but it seems likely that an unknown agent or agents cause pulmonary vasoconstriction, possibly in the presence of some predisposing factor, before the development of irreversible organic changes in the pulmonary vasculature."5 Treatment with a pulmonary vasodilator at this stage might reverse the process, though this cannot be expected when the stage of progressive fibrous vascular occlusion with plexiform and dilatation lesions has been reached.
